Supernus Pharmaceuticals
Rockville, Maryland, United States · Biopharma, Biotechnology, Health Care
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company has a significant experience in CNS and has successfully introduced more than eight widely recognized products in this therapeutic category. Their recent advancement includes ONAPGO, a subcutaneous apomorphine
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 180
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (SUPN)
- Website
- supernus.com
Recent activity at Supernus Pharmaceuticals
- : SEC 8-K (8.01): On October 21, 2026, Supernus Pharmaceuticals, Inc. announced that the FDA has granted seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl), which is used for treating motor fluctuations in adults with advanced Parkinson's disease. This exclusivity, effective from February 3, 2025, is vital for the company's competitive positioning in the market. Additionally, the Company submitted a supplemental New Drug Application for a second supplier of ONAPGO, anticipating FDA approval by mid-2027, which may further strengthen its supply chain and market presence.
- : Supernus acquires SAGE Therapeutics for USD 8.50/share
- : Supernus to merge with Indivior Pharmaceuticals
- : SEC 8-K (8.01): On August 3, 2026, Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. announced a proposed merger during a conference call. The companies will discuss important details regarding their merger, including plans to file a registration statement on Form S-4 with the SEC, which will serve as a joint proxy statement and prospectus. Investors are encouraged to read the forthcoming documents for crucial details about the transaction. The report emphasizes that this information is for informational purposes only and does not constitute an offer to buy or sell securities.
- : SEC 8-K (8.01): On August 3, 2026, Supernus Pharmaceuticals, Inc. announced a proposed merger of equals with Indivior Pharmaceuticals Inc. through a LinkedIn post and internal communications to its employees. The communications included an email from President and CEO Jack A. Khattar and a presentation for staff meetings. This merger aims to combine resources and enhance market presence, signaling a strategic consolidation in the pharmaceutical sector. Important documentation regarding the merger, including a registration statement on Form S-4, is to be filed with the SEC for transparency and compliance, with additional information available through both companies' websites.
- : SEC 8-K (5.02): On August 1, 2026, the Company and its President and CEO, Jack A. Khattar, entered into a Second Amended and Restated Employment Agreement, which will take effect only upon the consummation of a Merger Agreement. The new agreement supersedes his prior employment agreement and outlines an annual base salary of $1,115,000 with a cash bonus potential based on performance goals. In case of termination without cause or for good reason, Khattar is entitled to severance benefits including salary continuation, a lump-sum bonus payment, and COBRA premiums. The agreement contains standard confidentiality, non-competition, and non-solicitation clauses, with specific board approval required for termination for cause during a three-year period following the merger. The event of descending to this employment arrangement is significant as it highlights the leadership structure following the merger and the compensation strategy in alignment with the company’s goals.
- : Supernus Pharmaceuticals Expands Partnership with MERGE for Digital Marketing.
- : SEC 8-K (2.03): On May 17, 2026, Supernus Pharmaceuticals, Inc. reported the achievement of Milestone 1 as defined in their Contingent Value Right Agreement, which occurred on March 18, 2026. The company is obligated to make a milestone payment of $0.50 per Contingent Value Right (CVR), totaling approximately $33.4 million. This payment, to be made in cash, is subject to applicable withholding taxes and reflects a significant financial obligation for the company as part of its strategic goals outlined in the CVR Agreement.
- : SEC 8-K (1.01):
- : SEC 8-K (5.02):
Leadership
- Barry, CEO
- Ray, Regional Business Director
- Mollie Baird, Vice President, Head of Clinical Development Operations
- Safet Palamar, DMPK Informatics Analyst
Verified email and direct lines for Supernus Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Supernus Pharmaceuticals files 5 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Supernus Pharmaceuticals in the news
- Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) - GlobeNewswire (Oct 21, 2026)
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugs - BioSpace (Aug 03, 2026)
- Supernus, Indivior merge to strengthen neuroscience drug portfolio - Reuters (Aug 03, 2026)
- Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News (Aug 03, 2026)
- The results webcast will be available for 60 days after Supernus' Oct. 29 call. - Stock Titan (Oct 19, 2026)
- Supernus, Indivior merge to create CNS-focused company and expand BD opportunities - Fierce Pharma (Aug 03, 2026)
- Sage, following setbacks, to sell to Supernus for $561M - BioPharma Dive (Jun 16, 2025)
- Supernus and Indivior merge to create scaled, CNS-focused entity - Pharmaceutical Technology (Aug 04, 2026)
Companies similar to Supernus Pharmaceuticals
- TerSera · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Disc · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Avadel · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Parabilis Medicines · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Aurinia Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Supernus Pharmaceuticals: questions and answers
What does Supernus Pharmaceuticals do?
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company has a significant experience in CNS and has successfully introduced more than eight widely recognized products in this therapeutic category. Their recent advancement includes ONAPGO, a subcutaneous apomorphine
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is headquartered in Rockville, Maryland, United States.
How many employees does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has about 180 employees.
Who leads Supernus Pharmaceuticals?
Barry is a CEO at Supernus Pharmaceuticals.
What is the latest news on Supernus Pharmaceuticals?
On Oct 21, 2026, SEC 8-K (8.01): On October 21, 2026, Supernus Pharmaceuticals, Inc. announced that the FDA has granted seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl), which is used for treating motor fluctuations in adults with advanced Parkinson's disease. This exclusivity, effective fr
Is Supernus Pharmaceuticals a public company?
Yes. Supernus Pharmaceuticals is publicly traded under the ticker SUPN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy